Quest Licenses Another Epigenomics Biomarker | GenomeWeb

NEW YORK (GenomeWeb News) — Quest Diagnostics has licensed a biomarker for prostate cancer from Epigenomics, which it plans to use to develop a molecular diagnostic test for diagnosing the disease, Epigenomics said today.

The agreement gives Quest the rights to use the GSTP1 DNA methylation biomarker in order to both develop and market the diagnostic test, which will be performed using patient tissue samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.